Article Sidebar

pdf
Date Published: 02/12/2024
Abstract Views: 181
Views pdf: 106
DOI: https://doi.org/10.51298/vmj.v544i3.12029
Issue
Vol. 544 No. 3 (2024)
Section
Các bài báo
How to Cite
Lê, T. M. D., & Nguyễn, T. T. (2024). COMPARISON OF THE VALUE OF SINGLE BIOMARKERS PLGF, PAPP-A WITH THE COMBINED BIOMARKERS PLGF – PAPP-A IN ASSESSING THE RISK OF PRE-ECLAMPSIA DURING PREGNANCY. Vietnam Medical Journal, 544(3). https://doi.org/10.51298/vmj.v544i3.12029

COMPARISON OF THE VALUE OF SINGLE BIOMARKERS PLGF, PAPP-A WITH THE COMBINED BIOMARKERS PLGF – PAPP-A IN ASSESSING THE RISK OF PRE-ECLAMPSIA DURING PREGNANCY

Thị Mai Dung Lê, Trọng Thực Nguyễn

Main Article Content

Abstract

Objective: To compare the value of biomarkers PLGF and PAPP-A when used individually and in combination in assessing the risk of pre-eclampsia (PE) during pregnancy. Subjects and Methods: The study included 249 pregnant women between 11 and 13 weeks 6 days who were indicated for pre-eclampsia screening tests at STO Phuong Dong Hospital. Information on the pregnant women and retrospective test results for PLGF and PAPP-A were collected from the data of these women from February 2022 to March 2023. PLGF and PAPP-A results were obtained from the Thermo Fisher Scientific BRAHMSTM KRYPTORTM compact PLUS system using TRACE technology principles. Pre-eclampsia risk assessment was conducted using the BRAHMS Fast Screen pre1 plus/v3.1 software. Data analysis was performed using STATA 14.0 software with Wilcoxon signed-rank test and Kruskal-Wallis test for non-normally distributed data. Results: The risk value of pre-eclampsia before 34 weeks assessed from the PLGF or PLGF-PAPP-A markers showed no significant difference. Comparing the use of PAPP-A with the combined marker PLGF-PAPP-A showed a difference in risk value, with a significantly higher number of high-risk cases between 34 weeks and before 37 weeks. Conclusion: Using the single marker PLGF to assess the risk of preeclampsia in the first trimester of pregnancy on the risk assessment model has similarities with the combined use of the two markers PLGF and PAPP-A better than when using single marker PAPP-A

Article Details

References

1. Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275-289.
2. Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014;34(7):618-627.
3. Tan MY, Syngelaki A, Poon LC, et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2018;52(2):186-195.
4. O’Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(1): 103.e1-103.e12.
5. Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Da Silva AB, Nicolaides KH. Screening for pre-eclampsia at 11–13 weeks’ gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet Gynecol. 2020; 56(3):400-407.
6. Wright D, Tan MY, O’Gorman N, Syngelaki A, Nicolaides KH. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. BJOG Int J Obstet Gynaecol. 2022;129(8):1308-1317.